A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response

Inclusion Criteria:

• Inclusion criteria for enrolment

• Subjects who, in the opinion of the investigator, can and will comply with therequirements of the protocol or/and subjects' Legally AcceptableRepresentative(s) [LAR(s)] who, in the opinion of the investigator, can andwill comply, with the requirements of the protocol.

• Written informed consent obtained from the subject/LAR(s) of the subject priorto performance of any study-specific procedure.

• Subjects who previously participated in study ZOSTER-041 and completed the full 2 dose HZ/su primary vaccination course.

• Inclusion criteria for revaccination

• Subjects receiving maintenance CIS therapy for the prevention of allograftrejection for a minimum of one month prior to the first revaccination.

• Subjects without an episode of allograft rejection within 90 days prior to thefirst revaccination visit.

• Female subjects of non-childbearing potential may be revaccinated.Non-childbearing potential is defined as pre-menarche, current bilateral tuballigation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause.

• Female subjects of childbearing potential may be revaccinated, if the subject:

• has practiced adequate contraception for 30 days prior to revaccination, and

• has a negative pregnancy test on the day of revaccination, and

• has agreed to continue adequate contraception up to 2 months after completion of therevaccination series.

Exclusion Criteria:

Exclusion criteria for enrolment Medical conditions

• Vaccination against HZ since completion of study ZOSTER-041.

• Significant underlying illness that, in the opinion of the investigator, is expectedto prevent completion of the study.

• Any other condition that, in the opinion of the investigator, would interfere withthe evaluations required by the study.

Prior/Concurrent clinical study experience

• Concurrently participating in another interventional vaccine or immunosuppressive clinical study, in which the subject is exposed to an investigational or a non-investigational vaccine/product (drug) at any time during the ZOSTER-073 study.

Exclusion criteria for revaccination Medical conditions

• History of confirmed HZ within one year before revaccination visit (Visit 3).

• More than one organ transplanted.

• Any additional confirmed or suspected immunosuppressive or immunodeficientcondition.

• History of any reaction or hypersensitivity likely to be exacerbated by anycomponent of the vaccine.

• Any other condition that, in the opinion of the investigator, would interfere withthe evaluations required by the study or make vaccination unsafe.

Prior/Concomitant therapy

• Administration or planned administration of immunoglobulins and/or any bloodproducts or plasma derivatives during the period starting 3 months before the firstrevaccination dose of study vaccine and ending at Visit 5 (Month 26).

• Use of anti-CD20 or other B-cell monoclonal antibody agents as maintenance and/ortherapeutic immunosuppressive therapy for the prevention of allograft rejectionwithin 9 months of first revaccination dose of study vaccine.

• Evidence or high suspicion, in the opinion of the investigator, of noncompliance ornonadherence to use of maintenance immunosuppressive therapies.

• Planned administration/administration of a live vaccine in the period starting 30days before the first dose and ending 30 days after the last dose of study vaccineadministration.

• Planned administration/administration of a non-replicating or subunit vaccine, notforeseen by the study protocol, in the period starting 8 days before and ending 30days after each dose of study vaccine.

Other exclusion criteria for revaccination

• Pregnant or lactating female.

• Female planning to become pregnant or planning to discontinue contraceptiveprecautions up to 2 months post-revaccination Dose 2.

• Any condition which, in the judgment of the investigator, would make intramuscularinjection unsafe.